However, some evidences, obtained by us [99] in human gliomas at different grades of malignancy, strongly indicate an upregulation of PPARα and its direct relationship with malignancy grade, suggesting that PPARα antagonists can be used to halt malignancy, and suggesting that in some cases dual PPAR agonists should be carefully used. Here, PPARA is linked to central nervous system cancer.